Literature DB >> 17637571

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

Gretchen S Jimenez1, Rodrick Planchon, Qun Wei, Denis Rusalov, Andrew Geall, Joel Enas, Peggy Lalor, Vicky Leamy, Ruth Vahle, Catherine J Luke, Alain Rolland, David C Kaslow, Larry R Smith.   

Abstract

Next generation influenza vaccines containing conserved antigens may enhance immunity against seasonal or pandemic influenza virus strains. Using a plasmid DNA (pDNA)-based vaccine approach, we systematically tested combinations of NP, M1, and M2 antigens derived from consensus sequences for protection against lethal influenza challenge and compared formulations for adjuvanting low pDNA vaccine doses. The highest level of protection at the lowest pDNA doses was provided by Vaxfectin-formulated NP + M2. Vaxfectin adjuvanticity was confirmed with a low dose of HA pDNA. These promising proof-of-concept data support the clinical development of Vaxfectin-formulated pDNA encoding NP + M2 consensus proteins.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17637571     DOI： 10.4161/hv.3.5.4175

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


  33 in total

Review 1.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

Review 2.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

3.  Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Authors:  Wenling Wang; Renqing Li; Yao Deng; Ning Lu; Hong Chen; Xin Meng; Wen Wang; Xiuping Wang; Kexia Yan; Xiangrong Qi; Xiangmin Zhang; Wei Xin; Zhenhua Lu; Xueren Li; Tao Bian; Yingying Gao; Wenjie Tan; Li Ruan
Journal:  Clin Vaccine Immunol       Date:  2015-04-01

4.  Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.

Authors:  Glendie Marcelin; Hilliary M Bland; Nicholas J Negovetich; Matthew R Sandbulte; Ali H Ellebedy; Ashley D Webb; Yolanda S Griffin; Jennifer L DeBeauchamp; Janet E McElhaney; Richard J Webby
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

5.  Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.

Authors:  Frédéric Kendirgi; Nadezda E Yun; Nathaniel S Linde; Michele A Zacks; Jeanon N Smith; Jennifer K Smith; Harilyn McMicken; Yin Chen; Slobodan Paessler
Journal:  Hum Vaccin       Date:  2008-11-21

6.  The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.

Authors:  Petr O Ilyinskii; Anatoli B Meriin; Vladimir L Gabai; Evgeny V Usachev; Alexei G Prilipov; Galini Thoidis; Alexander M Shneider
Journal:  Protein Sci       Date:  2008-04-14       Impact factor: 6.725

7.  The signal peptide sequence impacts the immune response elicited by a DNA epitope vaccine.

Authors:  Dimitrios Vatakis; Minnie McMillan
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

8.  Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses.

Authors:  Shahla Shahsavandi; Mohammad Majid Ebrahimi; Kaveh Sadeghi; Homayoon Mahravani
Journal:  Virol Sin       Date:  2015-04-15       Impact factor: 4.327

9.  Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret.

Authors:  Srinivas S Rao; Wing-Pui Kong; Chih-Jen Wei; Neal Van Hoeven; J Patrick Gorres; Martha Nason; Hanne Andersen; Terrence M Tumpey; Gary J Nabel
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

10.  Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines.

Authors:  Paul Thiamjoo Tan; A T Heiny; Olivo Miotto; Jerome Salmon; Ernesto T A Marques; Francois Lemonnier; J Thomas August
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.